All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia

Gerardo Quezada, Lisa Kopp, Elihu Estey, Robert J. Wells

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML). Treatment of pediatric APL is based on the combination of all-trans-retinoic acid (ATRA), an anthracycline and cytosine arabinoside. Arsenic trioxide (ATO) has been studied in adults with newly diagnosed or relapsed APL with excel lent response rates both when used as a single agent or in combination with ATRA or ATRA plus chemotherapy. There is little data on combination therapy with ATRA and ATO in pediatric APL. We present a case of an adolescent male with APL who was treated using ATRA and ATO without conventional chemotherapy agents.

Original languageEnglish (US)
Pages (from-to)133-135
Number of pages3
JournalPediatric Blood and Cancer
Volume51
Issue number1
DOIs
StatePublished - Jul 1 2008
Externally publishedYes

Keywords

  • APL
  • ATRA
  • Arsenic trioxide
  • Pediatric APL

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia'. Together they form a unique fingerprint.

  • Cite this